[Physico-chemical and toxicological profile of gadolinium chelates as contrast agents for magnetic resonance imaging].
Gadolinium chelates (GC) are contrast agents widely used to facilitate or to enable diagnosis using magnetic resonance imaging (MRI). From a regulatory viewpoint, GC are drugs. GC have largely contributed to the success of MRI, which has become a major component of clinician's diagnostic armamentarium. GC are not metabolised and are excreted by the kidneys. They distribute into the extracellular compartment. Because of its high intrinsic toxicity, gadolinium must be administered as a chelate. GC can be classified according to two key molecular features: (a) nature of the chelating moiety: either macrocyclic molecules in which gadolinium is caged in the pre-organized cavity of the ligand, or linear, open-chain molecules, (b) ionicity: Gd chelates can be ionic (meglumine or sodium salts) or non-ionic. The thermodynamic and kinetic stabilities of the various GCs differ according to these structural characteristics. The kinetic stability of macrocyclic GCs is much higher than that of linear GCs and the thermodynamic stability of ionic GCs is generally higher than that of non-ionic GC, thus leading to a lower risk of gadolinium dissociation. This class of drugs has enjoyed an excellent reputation in terms of safety for a long time, until a causal link with a recently-described serious disease, nephrogenic systemic fibrosis (NSF), was evidenced. It is acknowledged that the vast majority of NSF cases are related to the administration of some linear CG in renally-impaired patients. Health authorities, worldwide, released recommendations which drastically reduced the occurrence of new cases.
Guerbet, division recherche et innovation, BP 57400, 95943 Roissy-Charles De Gaulle cedex, France. Electronic address: ideej@guerbet-group.com.
J-M
JM
Idée
Guerbet, division recherche et innovation, BP 57400, 95943 Roissy-Charles De Gaulle cedex, France.
N
N
Fretellier
Département de radiologie, CHU de Vienne, AKH, Vienne, Autriche.
M M
MM
Thurnher
Guerbet, division recherche et innovation, BP 57400, 95943 Roissy-Charles De Gaulle cedex, France.
B
B
Bonnemain
Guerbet, division recherche et innovation, BP 57400, 95943 Roissy-Charles De Gaulle cedex, France.
C
C
Corot
D000818:Animals; D002614:Chelating Agents; D003287:Contrast Media / Q000737:chemistry* / Q000633:toxicity*; D005682:Gadolinium / Q000737:chemistry* / Q000633:toxicity*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*
D002614:Chelating Agents; D003287:Contrast Media; D005682:Gadolinium
Agents de contraste; Chélates de gadolinium; Contrast agents; Fibrose systémique néphrogénique; Gadolinium; Gadolinium chelates; Imagerie par résonance magnétique; Magnetic resonance imaging; Nephrogenic systemic fibrosis